Caveolin‐1 overexpression is associated with aggressive prostate cancer recurrence

Caveolin‐1 protein suppresses apoptotic cell death in prostate cancer. The objectives of this study were to investigate the association of Caveolin‐1 expression with established features of prostate cancer as well as overall and aggressive disease recurrence in patients treated with radical prostatectomy (RP).

[1]  M. Lisanti,et al.  The Caveolin genes: from cell biology to medicine , 2004, Annals of medicine.

[2]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[3]  L. Truong,et al.  Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. , 1999, Cancer research.

[4]  M. Drab,et al.  Loss of Caveolae, Vascular Dysfunction, and Pulmonary Defects in Caveolin-1 Gene-Disrupted Mice , 2001, Science.

[5]  T. Stamey,et al.  Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.

[6]  Sun-Ja Kim,et al.  Increased expression of caveolin‐1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma , 2004, BJU international.

[7]  M. Kattan,et al.  Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor β1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression , 2004, Clinical Cancer Research.

[8]  M. Lisanti,et al.  Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle Cells , 1996, The Journal of Biological Chemistry.

[9]  A. Partin,et al.  Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.

[10]  S. Woodman,et al.  Caveolae: From Cell Biology to Animal Physiology , 2002, Pharmacological Reviews.

[11]  C. Peschle,et al.  Expression of Caveolin-1 Is Required for the Transport of Caveolin-2 to the Plasma Membrane , 1999, The Journal of Biological Chemistry.

[12]  Pan‐Chyr Yang,et al.  Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. , 2002, The American journal of pathology.

[13]  M. Lisanti,et al.  Caveolin-1 in oncogenic transformation, cancer, and metastasis. , 2005, American journal of physiology. Cell physiology.

[14]  G. Fiucci,et al.  Up-regulation of Caveolae and Caveolar Constituents in Multidrug-resistant Cancer Cells* , 1998, The Journal of Biological Chemistry.

[15]  L. Campbell,et al.  Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma , 2003, British Journal of Cancer.

[16]  C. Roehrborn,et al.  Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. , 2004, The Journal of urology.

[17]  M. Lisanti,et al.  Upregulation of caveolin‐1 and caveolae organelles in Taxol‐resistant A549 cells , 1998, FEBS letters.

[18]  T. Daskivich,et al.  Recent progress in hormonal therapy for advanced prostate cancer , 2006, Current opinion in urology.

[19]  William J Catalona,et al.  Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. , 2004, The Journal of urology.

[20]  M. Kattan,et al.  Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. , 2003, Cancer research.

[21]  T. Timme,et al.  Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells , 1998, Nature Medicine.

[22]  T. Timme,et al.  Combined c‐Myc and caveolin‐1 expression in human prostate carcinoma predicts prostate carcinoma progression , 2005, Cancer.

[23]  T. Wheeler,et al.  Elevated caveolin-1 levels in African-American versus white-American prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  D. Henson,et al.  Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. A publication of the cancer committee, college of american pathologists. Task Force on the Examination of Specimens Removed From Patients With Prostate Cancer. , 1994, Archives of pathology & laboratory medicine.

[25]  T. Wheeler,et al.  Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort , 2006, Clinical Cancer Research.

[26]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[27]  V. Barresi,et al.  Caveolin-1 in meningiomas: expression and clinico-pathological correlations , 2006, Acta Neuropathologica.

[28]  M. Lisanti,et al.  Expression and Characterization of Recombinant Caveolin , 1996, The Journal of Biological Chemistry.

[29]  C. Roehrborn,et al.  Survivin expression is associated with features of biologically aggressive prostate carcinoma , 2004, Cancer.

[30]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[31]  T. Timme,et al.  Caveolin‐1 expression is a predictor of recurrence‐free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients , 2003, Cancer.

[32]  J. Engelman,et al.  Genes encoding human caveolin‐1 and ‐2 are co‐localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers , 1998, FEBS letters.

[33]  Michael W Kattan,et al.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.

[34]  M. Kattan,et al.  Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. , 2002, Cancer research.